drugset / Trial / NCT05353894

Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers

NCT05353894

Phase 1 Unknown 27 enrolled Genoscience Pharma
Non-randomizedCrossoverOpen-labelTreatment

Summary

GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare pharmacokinetics, safety and tolerability of different formulations (tablets and capsules) and dosage (50 and 200mg) of GNS561 after single oral administration in first part and to evaluate the food effect on pharmacokinetics in second part.

Timeline

Start
2022-05-02
Primary completion
2022-11-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezurpimtrostat Small molecule 50 mg Oral
Subject Ezurpimtrostat Small molecule 200 mg Oral

Indications